Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

摘要: Alfuzosin, a new quinazoline derivative, acts as selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction prostatic, prostatic capsule, bladder base proximal urethral smooth muscle, thereby reducing the tone these structures. Consequently, pressure resistance, outlet instability symptoms associated with benign hyperplasia are reduced. A limited range clinical studies have shown oral alfuzosin to be more effective than placebo (in < or = 6 months duration), sustained effects on long term administration (< 30 months), comparable 1-adrenoceptor prazosin, in symptomatic treatment hyperplasia. This is reflected increases urinary flow rate decreases symptom score residual volume. The most marked improvements occur patients severe pretreatment abnormalities. Furthermore, preliminary results suggest beneficial effect quality life overall incidence adverse appears similar that placebo, vasodilatory-related lower prazosin. relative selectivity for 1-adrenoceptors genitourinary tract compared receptors vasculature potential advantage over other alpha-adrenoceptor antagonists, including may reduced by at doses minimal vasodilatory effects, minimising postural hypotension syncope. However, common alfuzosin, dose first-dose hypotensive relationships, especially elderly, cannot excluded this stage use alfuzosin. full will clarified further comparative (with large patient numbers) against antagonists. Nevertheless, 7.5 10 mg/day divided promising first-line agent noncomplicated mild moderate high dynamic component their obstruction. In addition, offers an alternative prostatectomy (the current 'gold standard') who require surgery but unfit treatment, requiring relief while awaiting surgery.